Identification

Name
Moxifloxacin
Accession Number
DB00218  (APRD00281)
Type
Small Molecule
Groups
Approved, Investigational
Description

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Structure
Thumb
Synonyms
  • 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
External IDs
BAY 12-8039
Product Ingredients
IngredientUNIICASInChI Key
Moxifloxacin hydrochlorideC53598599T186826-86-8IDIIJJHBXUESQI-DFIJPDEKSA-N
Moxifloxacin hydrochloride monohydrateB8956S8609192927-63-2SKZIMSDWAIZNDD-WJMOHVQJSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act MoxifloxacinSolution0.5 %OphthalmicActavis Pharma Company2015-11-04Not applicableCanada
Auro-moxifloxacinTablet400 mgOralAuro Pharma Inc2015-11-04Not applicableCanada
AveloxTablet, film coated400 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-12-07Not applicableUs
AveloxTablet, film coated400 mg/1OralRed Pharm Drug, Inc.2011-02-25Not applicableUs
AveloxTablet, film coated400 mg/1OralSchering Plough1999-12-10Not applicableUs
AveloxTablet, film coated400 mg/1OralBayer1999-12-10Not applicableUs
AveloxTablet, film coated400 mg/1OralRemedy Repack2013-05-242017-03-03Us00085 1733 03 nlmimage10 2619935c
AveloxTablet, film coated400 mg/1OralCardinal Health2010-03-02Not applicableUs
AveloxTablet400 mgOralBayer2000-10-20Not applicableCanada
AveloxTablet, film coated400 mg/1OralPhysicians Total Care, Inc.2009-07-16Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-moxifloxacinTablet400 mgOralApotex Corporation2016-01-11Not applicableCanada
Apo-moxifloxacinSolution0.5 %OphthalmicApotex Corporation2015-11-19Not applicableCanada
MoxifloxacinTablet, film coated400 mg/1OralDr Reddy's Laboratories2014-03-05Not applicableUs
MoxifloxacinSolution / drops5 mg/mLOphthalmicApotex Corporation2017-07-01Not applicableUs
MoxifloxacinSolution / drops5 mg/mLOphthalmicAurobindo Pharma2017-10-04Not applicableUs
MoxifloxacinSolution / drops5 mg/mLOphthalmicLupin Pharmaceuticals2017-06-16Not applicableUs
MoxifloxacinTablet, film coated400 mg/1OralMajor2014-03-05Not applicableUs
Moxifloxacin HydrochlorideTablet, film coated400 mg/1OralCitron Pharma LLC2014-03-04Not applicableUs
Moxifloxacin HydrochlorideTablet400 mg/1OralFera Pharmaceuticals2016-01-222016-11-15Us
Moxifloxacin HydrochlorideTablet400 mg/1OralTorrent Pharmaceuticals Limited2014-04-03Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MoxifloxacinSolution / drops5 mg/mLOphthalmicAkorn2017-11-09Not applicableUs
Moxifloxacin Hydrochloride Tablets, 400 mgTablet, film coated400 mg/1OralMsn Laboratories Private Limited2017-09-22Not applicableUs
Categories
UNII
U188XYD42P
CAS number
151096-09-2
Weight
Average: 401.4314
Monoisotopic: 401.175084476
Chemical Formula
C21H24FN3O4
InChI Key
FABPRXSRWADJSP-MEDUHNTESA-N
InChI
InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
IUPAC Name
7-[(4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
[H][[email protected]]12CN(C[[email protected]@]1([H])NCCC2)C1=C(F)C=C2C(=O)C(=CN(C3CC3)C2=C1OC)C(O)=O

Pharmacology

Indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Structured Indications
Pharmacodynamics

Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, and Streptococcus viridans group. Aerobic Gram-negative microorganisms: Acinetobacter lwoffii, Haemophilus influenzae, and Haemophilus parainfluenzae. Other microorganisms: Chlamydia trachomatis.
Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Mechanism of action

The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

TargetActionsOrganism
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
UDNA topoisomerase 2-alpha
inhibitor
Human
Absorption

Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.

Volume of distribution
  • 1.7 to 2.7 L/kg
Protein binding

50% bound to serum proteins, independent of drug concentration.

Metabolism

Approximately 52% or oral or intravenous dose is metabolized via glucuronide and sulphate conjugation. The cytochrome P450 system is not involved in metabolism. The sulphate conjugate accounts for 38% of the dose, and the glucuronide conjugate accounts for 14% of the dose.

Route of elimination

Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces).

Half life

11.5-15.6 hours (single dose, oral)

Clearance
  • 12 +/- 2 L/hr
Toxicity

Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Moxifloxacin.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Moxifloxacin.Approved
AmiodaroneMoxifloxacin may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Moxifloxacin.Approved
AnagrelideMoxifloxacin may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Arsenic trioxideMoxifloxacin may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMoxifloxacin may increase the QTc-prolonging activities of Artemether.Approved
AsenapineMoxifloxacin may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirAtazanavir may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Moxifloxacin.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Moxifloxacin.Approved
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Moxifloxacin.Investigational
BedaquilineMoxifloxacin may increase the QTc-prolonging activities of Bedaquiline.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
BortezomibBortezomib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
BuserelinBuserelin may increase the QTc-prolonging activities of Moxifloxacin.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Moxifloxacin.Approved
CeritinibMoxifloxacin may increase the QTc-prolonging activities of Ceritinib.Approved
ChloroquineMoxifloxacin may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorpromazineMoxifloxacin may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
CiprofloxacinMoxifloxacin may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMoxifloxacin may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramMoxifloxacin may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinMoxifloxacin may increase the QTc-prolonging activities of Clarithromycin.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
ClozapineMoxifloxacin may increase the QTc-prolonging activities of Clozapine.Approved
CrizotinibMoxifloxacin may increase the QTc-prolonging activities of Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Moxifloxacin.Experimental
DabrafenibDabrafenib may increase the QTc-prolonging activities of Moxifloxacin.Approved
DasatinibDasatinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Moxifloxacin.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Moxifloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Moxifloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Moxifloxacin.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
DisopyramideMoxifloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Moxifloxacin.Approved, Investigational
DofetilideMoxifloxacin may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMoxifloxacin may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMoxifloxacin may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Moxifloxacin.Approved
DronedaroneMoxifloxacin may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolMoxifloxacin may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
EliglustatMoxifloxacin may increase the QTc-prolonging activities of Eliglustat.Approved
EribulinEribulin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
EscitalopramMoxifloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Moxifloxacin.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Moxifloxacin.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Moxifloxacin.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
FlecainideMoxifloxacin may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FluconazoleFluconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved
FluoxetineMoxifloxacin may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolMoxifloxacin may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FormoterolFormoterol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
FoscarnetFoscarnet may increase the QTc-prolonging activities of Moxifloxacin.Approved
Gadobenic acidMoxifloxacin may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Moxifloxacin.Approved
GemifloxacinMoxifloxacin may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Moxifloxacin.Experimental
GoserelinGoserelin may increase the QTc-prolonging activities of Moxifloxacin.Approved
GranisetronMoxifloxacin may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
HaloperidolMoxifloxacin may increase the QTc-prolonging activities of Haloperidol.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Moxifloxacin.Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Moxifloxacin.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
IbutilideMoxifloxacin may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneMoxifloxacin may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Moxifloxacin.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Moxifloxacin.Approved
ItraconazoleItraconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Moxifloxacin.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Moxifloxacin.Experimental
LapatinibLapatinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
LenvatinibMoxifloxacin may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
LevofloxacinMoxifloxacin may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Moxifloxacin.Approved
LopinavirMoxifloxacin may increase the QTc-prolonging activities of Lopinavir.Approved
LumefantrineMoxifloxacin may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Moxifloxacin.Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Moxifloxacin.Approved
MequitazineMoxifloxacin may increase the arrhythmogenic activities of Mequitazine.Approved
MethadoneMoxifloxacin may increase the QTc-prolonging activities of Methadone.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Moxifloxacin.Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Moxifloxacin.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Moxifloxacin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Moxifloxacin.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Moxifloxacin.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Moxifloxacin.Approved
NelfinavirNelfinavir may increase the QTc-prolonging activities of Moxifloxacin.Approved
NicardipineNicardipine may increase the QTc-prolonging activities of Moxifloxacin.Approved
NilotinibMoxifloxacin may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Moxifloxacin.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
OfloxacinMoxifloxacin may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Moxifloxacin.Experimental, Investigational
OlodaterolOlodaterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
OndansetronMoxifloxacin may increase the QTc-prolonging activities of Ondansetron.Approved
OuabainOuabain may decrease the cardiotoxic activities of Moxifloxacin.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Moxifloxacin.Approved, Vet Approved
PaliperidoneMoxifloxacin may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatMoxifloxacin may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParoxetineParoxetine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Moxifloxacin.Approved
PazopanibMoxifloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
PentamidineMoxifloxacin may increase the QTc-prolonging activities of Pentamidine.Approved
PerflutrenMoxifloxacin may increase the QTc-prolonging activities of Perflutren.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Moxifloxacin.Experimental
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Moxifloxacin.Approved
PimozideMoxifloxacin may increase the QTc-prolonging activities of Pimozide.Approved
PosaconazolePosaconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational, Vet Approved
PrimaquineMoxifloxacin may increase the QTc-prolonging activities of Primaquine.Approved
ProcainamideMoxifloxacin may increase the QTc-prolonging activities of Procainamide.Approved
PromazineMoxifloxacin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Moxifloxacin.Approved
PropafenoneMoxifloxacin may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational, Vet Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Moxifloxacin.Experimental
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved
QuetiapineMoxifloxacin may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineMoxifloxacin may increase the QTc-prolonging activities of Quinidine.Approved
QuinineMoxifloxacin may increase the QTc-prolonging activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Moxifloxacin.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Moxifloxacin.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
RitonavirRitonavir may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
SaquinavirMoxifloxacin may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
SertralineSertraline may increase the QTc-prolonging activities of Moxifloxacin.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Moxifloxacin.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
SotalolMoxifloxacin may increase the QTc-prolonging activities of Sotalol.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Moxifloxacin.Approved
SulfisoxazoleMoxifloxacin may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SunitinibSunitinib may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Moxifloxacin.Approved
TelavancinMoxifloxacin may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMoxifloxacin may increase the QTc-prolonging activities of Telithromycin.Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Moxifloxacin.Approved
TetrabenazineMoxifloxacin may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineMoxifloxacin may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Moxifloxacin.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Moxifloxacin.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
ToremifeneMoxifloxacin may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Moxifloxacin.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Moxifloxacin.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Moxifloxacin.Approved, Vet Approved
VandetanibMoxifloxacin may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Moxifloxacin.Approved
VemurafenibMoxifloxacin may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Moxifloxacin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Moxifloxacin.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
ZiprasidoneMoxifloxacin may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolMoxifloxacin may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Drink liberally. Absorption is not affected by lipid-rich meals or yogourt.

References

Synthesis Reference

Manne Reddy, Sajja Eswaraiah, Vetukuri Venkata Naga Raju, Rapolu Kumar, Ningam Srinivasreddy, Vedantham Ravindra, "Crystalline form III of anhydrous moxifloxacin hydrochloride and a process for preparation thereof." U.S. Patent US20050137227, issued June 23, 2005.

US20050137227
General References
  1. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis. 2003 Dec 1;37(11):1448-52. Epub 2003 Nov 4. [PubMed:14614666]
External Links
Human Metabolome Database
HMDB14363
KEGG Drug
D08237
KEGG Compound
C07663
PubChem Compound
152946
PubChem Substance
46508509
ChemSpider
134802
BindingDB
50366824
ChEBI
63611
ChEMBL
CHEMBL32
Therapeutic Targets Database
DAP000158
PharmGKB
PA450555
HET
MFX
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Moxifloxacin
ATC Codes
J01MA14 — MoxifloxacinS01AE07 — Moxifloxacin
AHFS Codes
  • 52:04.04 — Antibacterials
  • 08:12.18 — Quinolones
PDB Entries
2xkk / 3fof / 4z2c / 4z3o / 5bs8 / 5bta / 5cdq
FDA label
Download (162 KB)
MSDS
Download (193 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableAlzheimer's Disease (AD)1
1CompletedNot AvailableCardiac Repolarization / Healthy Volunteers1
1CompletedNot AvailableCardiodynamics / Pharmacokinetics / Safety / Tolerability1
1CompletedNot AvailableChronic Hepatitis C Infection1
1CompletedNot AvailableClinical Pharmacology, Healthy Volunteer Study1
1CompletedNot AvailableContraception1
1CompletedNot AvailableFunctional Dyspepsia1
1CompletedNot AvailableHIV-infection/Aids1
1CompletedNot AvailableHealthy Volunteers17
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole1
1CompletedNot AvailableHeart Repolarization1
1CompletedNot AvailableLice Infestations1
1CompletedNot AvailableQt Interval, Variation in1
1CompletedBasic ScienceAlzheimer's Disease (AD)1
1CompletedBasic ScienceAmount of NKTR-118 in Blood / Variation in the Heart's Electrical Cycle1
1CompletedBasic ScienceAsthma Bronchial1
1CompletedBasic ScienceBacterial Infections1
1CompletedBasic ScienceC-Peptide Effects on the QT/QTc Interval / Effects of Different Meals on the QT/QTc Interval / Insulin and Oral Hypoglycemic [Antidiabetic] Drugs Causing Adverse Effects in Therapeutic Use / Japanese vs. Caucasian TQT Comparison / Moxifloxacin ECG Profile in Fed and Fasted State1
1CompletedBasic ScienceChronic Lung Diseases / Chronic Obstructive Pulmonary Disease (COPD)1
1CompletedBasic ScienceDrug-induced QT Interval Prolongation / Pharmacodynamics / Pharmacokinetics1
1CompletedBasic ScienceEffects of Sativex on ECG1
1CompletedBasic ScienceFibromyalgia1
1CompletedBasic ScienceHealthy Male Volunteers1
1CompletedBasic ScienceHealthy Volunteers14
1CompletedBasic ScienceHealthy Volunteers / Type 2 Diabetes Mellitus1
1CompletedBasic ScienceInfection NOS1
1CompletedBasic ScienceMalignant Lymphomas / Refractory Solid Tumors1
1CompletedBasic SciencePharmacokinetics1
1CompletedBasic ScienceRestless Legs Syndrome (RLS)1
1CompletedBasic ScienceRheumatoid Arthritis1
1CompletedBasic ScienceSchizophrenic Disorders1
1CompletedBasic ScienceTTR Cardiomyopathy1
1CompletedBasic ScienceTumors, Solid1
1CompletedBasic ScienceType 2 Diabetes Mellitus1
1CompletedDiagnosticHealthy Volunteers1
1CompletedDiagnosticHuman Volunteers1
1CompletedDiagnosticTherapeutic Agent Toxicity1
1CompletedDiagnosticThe Effect of Moxifloxacin on QT/QTc Interval1
1CompletedEducational/Counseling/TrainingPatients With Pace Makers But no Evidence of Ischemic Heart Disease1
1CompletedOtherCardiovascular Abnormalities1
1CompletedOtherHealthy Volunteers1
1CompletedOtherMalaria caused by plasmodium vivax1
1CompletedOtherNausea and Vomiting, Postoperative / Prophylaxis of acute chemotherapy induced nausea and vomiting1
1CompletedOtherTuberculosis1
1CompletedPreventionHealthy Volunteers3
1CompletedScreeningCataract Extraction1
1CompletedScreeningHealthy Volunteers1
1CompletedTreatmentAcne Vulgaris1
1CompletedTreatmentAcute Coronary Syndromes (ACS)1
1CompletedTreatmentAlzheimer's Disease (AD) / Healthy Volunteers1
1CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
1CompletedTreatmentAnemias2
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCardiac Conduction and Repolarization1
1CompletedTreatmentCardiac Effects in Normal Healthy Volunteers1
1CompletedTreatmentCardiac Repolarization in Healthy Subjects1
1CompletedTreatmentCardiac Repolarization / Healthy Volunteers1
1CompletedTreatmentChronic Hepatitis C Infection2
1CompletedTreatmentChronic Lung Diseases / Moxifloxacin / Pulmonary Diseases1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Healthy Volunteers1
1CompletedTreatmentCystic Fibrosis (CF)1
1CompletedTreatmentDiabetes / Healthy Volunteers1
1CompletedTreatmentDiabetes / Type 2 Diabetes Mellitus1
1CompletedTreatmentDyslipidemias2
1CompletedTreatmentECG Effects1
1CompletedTreatmentElectrocardiography / QTc Evaluation1
1CompletedTreatmentEpilepsies1
1CompletedTreatmentErectile Dysfunction (ED)1
1CompletedTreatmentHealthy Adult Male and Female Volunteers1
1CompletedTreatmentHealthy Volunteers52
1CompletedTreatmentHuman Experimentation (Human Volunteers)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHypertensive1
1CompletedTreatmentNormal Healthy Subjects1
1CompletedTreatmentObstetric Labour, Premature1
1CompletedTreatmentOccasional Constipation1
1CompletedTreatmentParkinson's Disease (PD)2
1CompletedTreatmentPhenylketonuria (PKU)1
1CompletedTreatmentPostoperative pain1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentQT Interval1
1CompletedTreatmentQTc Interval1
1CompletedTreatmentQt Interval, Variation in1
1CompletedTreatmentRenal Cell Adenocarcinoma / Tumors, Solid1
1CompletedTreatmentRespiratory Tract Infections (RTI)1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders1
1CompletedTreatmentTuberculosis1
1Not Yet RecruitingBasic ScienceDiabetes1
1RecruitingTreatmentTumors, Solid1
1TerminatedBasic ScienceHealthy Males1
1TerminatedOtherHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
1Unknown StatusTreatmentCardiac Toxicity1
1Unknown StatusTreatmentMycobacterium Tuberculosis1
1WithdrawnTreatmentAlzheimer's Disease (AD)1
1WithdrawnTreatmentAsthma Bronchial1
1WithdrawnTreatmentBacterial Infections2
1WithdrawnTreatmentTuberculosis1
1, 2CompletedPreventionRecurrent Tuberculosis1
1, 2CompletedTreatmentTB Multi-drug Resistant1
2Active Not RecruitingTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
2Active Not RecruitingTreatmentOff Episodes of Parkinson Disease / Parkinson's Disease (PD)1
2Active Not RecruitingTreatmentTuberculosis1
2CompletedNot AvailableCancers / Tumors, Solid1
2CompletedBasic ScienceHealthy Volunteers1
2CompletedBasic ScienceTuberculosis1
2CompletedTreatmentAcute Otitis Media1
2CompletedTreatmentCholangitis1
2CompletedTreatmentConjunctivitis, Bacterial1
2CompletedTreatmentPharmacodynamics / Pharmacokinetics / Tolerability / Tuberculous Meningitis1
2CompletedTreatmentPneumonia1
2CompletedTreatmentSpasticity1
2CompletedTreatmentTuberculosis5
2CompletedTreatmentTuberculosis, Pulmonary4
2Not Yet RecruitingTreatmentDrug-resistant Tuberculosis / Drug-Resistant Tuberculosis, Extremely / Tuberculosis / Tuberculosis, MDR / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2RecruitingPreventionEndophthalmitis1
2RecruitingTreatmentOsteomyelitis1
2TerminatedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)1
2TerminatedTreatmentCorneal Infiltrates1
2TerminatedTreatmentUlcerative keratitis1
2Unknown StatusTreatmentTuberculosis1
2, 3Not Yet RecruitingPreventionEndophthalmitis1
2, 3RecruitingTreatmentExtensively Drug-Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2, 3RecruitingTreatmentExtensively-drug Resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
3Active Not RecruitingTreatmentTuberculosis, Pulmonary, Drug Sensitive / Tuberculosis, Pulmonary, Multi Drug-resistant1
3CompletedPreventionBacteremia / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
3CompletedPreventionChronic Bronchitis / Chronic Lung Diseases1
3CompletedTreatmentAbscesses / Diabetic Foot / Ulcers / Wound Infections1
3CompletedTreatmentAcute Bacterial Conjunctivitis1
3CompletedTreatmentAcute Otitis Externa1
3CompletedTreatmentAcute Otitis Media1
3CompletedTreatmentCholecystitis, Acute1
3CompletedTreatmentChronic Bronchitis1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentCommunity Acquired Pneumonia (CAP)1
3CompletedTreatmentCommunity-Acquired Bacterial Pneumonia (CABP)2
3CompletedTreatmentCommunity-Acquired Infections / Pneumonia, Bacterial1
3CompletedTreatmentConjunctivitis, Bacterial2
3CompletedTreatmentBacterial blepharitis / Conjunctivitis / Corneal Inflammation1
3CompletedTreatmentInfection NOS1
3CompletedTreatmentInfectious Diseases1
3CompletedTreatmentIntra-Abdominal Infections1
3CompletedTreatmentIntraabdominal Infections1
3CompletedTreatmentLung Abscess / Pneumonia, Aspiration1
3CompletedTreatmentPelvic Inflammatory Disease (PID)2
3CompletedTreatmentPneumonia2
3CompletedTreatmentSevere Sepsis / Shock, Septic1
3CompletedTreatmentSinusitis1
3CompletedTreatmentTuberculosis, Pulmonary1
3Not Yet RecruitingTreatmentCataract operation / Endophthalmitis / Intracameral Antibiotics / Moxifloxacin / Phacoemulsification / Vancomycin1
3RecruitingPreventionEndophthalmitis1
3RecruitingTreatmentAtypical; Mycobacterium, Pulmonary, Tuberculous1
3RecruitingTreatmentCommunity Acquired Bacterial Pneumonia / Community Acquired Pneumonia (CAP)1
3RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
3RecruitingTreatmentKeratitis; Infectious Disease (Manifestation)1
3RecruitingTreatmentMDR-TB1
3RecruitingTreatmentTuberculosis2
3RecruitingTreatmentTuberculosis, Multidrug Resistant1
3TerminatedSupportive CareCancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Neuroblastomas / Testicular germ cell tumour1
3TerminatedTreatmentAcute Otitis Media1
3TerminatedTreatmentSkin Diseases, Infectious1
3TerminatedTreatmentTuberculous infections1
3Unknown StatusNot AvailableChronic Obstructive Pulmonary Disease (COPD)1
3Unknown StatusPreventionEye Infections1
3Unknown StatusTreatmentBacterial Infection Due to Helicobacter Pylori (H. Pylori) / Chronic Gastritis1
3Unknown StatusTreatmentCellulitis1
3WithdrawnTreatmentSkin Structures and Soft Tissue Infections1
4CompletedNot AvailableAbscesses / Cysts1
4CompletedNot AvailableCataract operation1
4CompletedNot AvailableCataract operation / Corneal Health1
4CompletedNot AvailableConjunctivitis, Bacterial1
4CompletedBasic ScienceAnti-Biotic Resistance1
4CompletedBasic ScienceCataracts1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedBasic ScienceSide-effect of Antibiotic1
4CompletedOtherCataract Extraction1
4CompletedOtherHealthy Volunteers1
4CompletedPreventionCataracts1
4CompletedSupportive CareAggressive Periodontitis / Generalized Aggressive Periodontitis1
4CompletedSupportive CareBacterial Infections / Cataract Extraction / Eye Infections1
4CompletedSupportive CareBacterial Infections / Eye Infections2
4CompletedTreatmentBody Weights / Bypass, Gastric1
4CompletedTreatmentCataract Extraction1
4CompletedTreatmentCataracts1
4CompletedTreatmentChronic Bronchitis1
4CompletedTreatmentChronic Generalized Periodontitis1
4CompletedTreatmentChronic Periodontitis1
4CompletedTreatmentConjunctivitis1
4CompletedTreatmentConjunctivitis, Bacterial2
4CompletedTreatmentEye Infections, Bacterial / Ulcerative keratitis1
4CompletedTreatmentHelicobacter Infections1
4CompletedTreatmentIntra-Abdominal Infections1
4CompletedTreatmentMaxillary Sinusitis1
4CompletedTreatmentPelvic Inflammatory Disease (PID)1
4CompletedTreatmentPneumonia1
4CompletedTreatmentProlonged QTc Interval1
4CompletedTreatmentHepatic abscess1
4Enrolling by InvitationPreventionCardiac Dysrhythmia1
4RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentCommunity Acquired Pneumonia (CAP)1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedBasic ScienceTransplantation, Corneal1
4TerminatedTreatmentBacterial Infections / Sinusitis1
4TerminatedTreatmentCommunity Acquired Pneumonia (CAP)1
4TerminatedTreatmentTuberculosis1
4Unknown StatusPreventionCataracts1
4Unknown StatusPreventionEye Infections / Infection NOS1
4Unknown StatusTreatmentCommunity Acquired Pneumonia (CAP)1
4Unknown StatusTreatmentIntravitreal Injection Patients1
4Unknown StatusTreatmentReinfection Pulmonary Tuberculosis1
Not AvailableCompletedNot AvailableAbscess, Intra-Abdominal / Secondary Peritonitis1
Not AvailableCompletedNot AvailableAcute Bacterial Sinusitis (ABS)1
Not AvailableCompletedNot AvailableAnti-Infective Agents1
Not AvailableCompletedNot AvailableBronchial Diseases / Chronic Bronchitis1
Not AvailableCompletedNot AvailableChronic Bronchitis2
Not AvailableCompletedNot AvailableChronic Bronchitis / Disease Exacerbation1
Not AvailableCompletedNot AvailableCorneal Epithelial Wound Healing1
Not AvailableCompletedNot AvailableDrug-Induced Liver Injury1
Not AvailableCompletedNot AvailablePneumonia1
Not AvailableCompletedNot AvailableSkin Diseases, Bacterial1
Not AvailableCompletedHealth Services ResearchHealthy Volunteers1
Not AvailableCompletedPreventionAge-Related Macular Degeneration (ARMD)1
Not AvailableCompletedPreventionInflammation Following Cataract Surgery1
Not AvailableCompletedPreventionPost Lasik Surgery Inflammation1
Not AvailableCompletedTreatmentEpithelium, Corneal1
Not AvailableCompletedTreatmentPeritoneal Dialysis Associated Peritonitis1
Not AvailableCompletedTreatmentPneumonia, Mycoplasma1
Not AvailableEnrolling by InvitationOtherAcute Appendicitis1
Not AvailableEnrolling by InvitationTreatmentHelicobacter Infection1
Not AvailableNot Yet RecruitingNot AvailableCommunity Acquired Pneumonia (CAP)1
Not AvailableNot Yet RecruitingDiagnosticLong qt Syndrome1
Not AvailableRecruitingTreatmentAcute Appendicitis1
Not AvailableRecruitingTreatmentBronchiectasis1
Not AvailableRecruitingTreatmentDrug-resistant Tuberculosis / Tuberculosis / Tuberculosis, Multidrug Resistant1
Not AvailableRecruitingTreatmentHelicobacter Infection1
Not AvailableTerminatedSupportive CareChronic Myeloproliferative Disorders / Fever, Sweats, and Hot Flashes / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Neutropenias / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableUnknown StatusTreatmentQT Interval Prolongation1
Not AvailableWithdrawnPreventionConjunctical Flora1

Pharmacoeconomics

Manufacturers
  • Bayer healthcare pharmaceuticals inc
  • Alcon inc
  • Bayer Healthcare Pharmaceuticals
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic0.5 %
Injection, solutionIntravenous400 mg/250mL
TabletOral400 mg
Tablet, film coatedOral400 mg/1
SolutionIntravenous400 mg
TabletOral400 mg/1
SolutionOphthalmic5 mg/mL
Solution / dropsOphthalmic5 mg/mL
Prices
Unit descriptionCostUnit
Vigamox 0.5% Solution 3ml Bottle90.72USD bottle
Vigamox 0.5% eye drops27.22USD ml
Avelox 400 mg tablet16.68USD tablet
Avelox abc pack 400 mg tablet16.35USD tablet
Avelox iv 400 mg/250 ml0.17USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4990517No1994-12-082011-12-08Us
CA2342211No2009-05-262019-09-29Canada
CA1340114No1998-11-032015-11-03Canada
US5849752No1996-12-052016-12-05Us
US6610327No1999-10-292019-10-29Us
US6548079No2000-07-252020-07-25Us
US7671070Yes2000-03-292020-03-29Us
US6716830Yes2000-03-292020-03-29Us
US8450311No2009-05-292029-05-29Us
US9114168No2009-05-292029-05-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)238-242 °CNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.168 mg/mLALOGPS
logP0.01ALOGPS
logP-0.5ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)5.69ChemAxon
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area82.11 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.22 m3·mol-1ChemAxon
Polarizability41.24 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9794
Blood Brain Barrier-0.9597
Caco-2 permeable-0.6093
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor INon-inhibitor0.7564
P-glycoprotein inhibitor IINon-inhibitor0.7181
Renal organic cation transporterNon-inhibitor0.7318
CYP450 2C9 substrateNon-substrate0.8018
CYP450 2D6 substrateNon-substrate0.8247
CYP450 3A4 substrateNon-substrate0.5756
CYP450 1A2 substrateNon-inhibitor0.7417
CYP450 2C9 inhibitorNon-inhibitor0.7735
CYP450 2D6 inhibitorNon-inhibitor0.8359
CYP450 2C19 inhibitorNon-inhibitor0.7401
CYP450 3A4 inhibitorNon-inhibitor0.8811
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5536
Ames testAMES toxic0.6227
CarcinogenicityNon-carcinogens0.9038
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8092
hERG inhibition (predictor II)Non-inhibitor0.6461
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0176900000-5ca9cd234a2a93f05658
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0391000000-7a74ddcc516a82243c1a

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyrrolopyridines / Pyridinecarboxylic acids / Methoxyanilines / Dialkylarylamines / Anisoles
show 15 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyrrolopyridine / Pyridine carboxylic acid or derivatives / Pyridine carboxylic acid / Methoxyaniline
show 33 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
aromatic ether, cyclopropanes, quinolone antibiotic, fluoroquinolone antibiotic, quinolone, quinolinemonocarboxylic acid, pyrrolidinopiperidine (CHEBI:63611)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779]
  4. Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5. [PubMed:10428935]
  5. Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC: gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002 Nov;46(11):3418-21. [PubMed:12384345]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29. [PubMed:17910998]
  4. Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19. [PubMed:16857688]
  5. Perez-Vazquez M, Roman F, Aracil B, Canton R, Campos J: Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol. 2004 Mar;42(3):1185-91. [PubMed:15004073]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Reuveni D, Halperin D, Shalit I, Priel E, Fabian I: Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. [PubMed:20596674]
  3. Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD: Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. doi: 10.1038/nsmb.1892. Epub 2010 Aug 29. [PubMed:20802486]

Drug created on June 13, 2005 07:24 / Updated on November 24, 2017 14:24